Alkem subsidiary Enzene launches adalimumab biosimilar in India

Enzene or its parent Alkem which is commercialising the drug didn't announce the price, but said it would be competitively priced.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/2rjv4Ll
via IFTTT